Tag Archives: Roswell Park Cancer Institute

OmniSeq, an innovation of Roswell Park Cancer Institute, announced today the commercial launch of Immune Report Card SM, the first immune profiling test designed to help oncologists select the best mono and combination immunotherapy options for their patients. The assay ...

Read More »